30 closest matches · ranked by relevance
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate (ORR) — 18.2 Percentage of Participants
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Non-small Cell Lung Cancer
Primary: 2-year Disease-free Survival — 88 Participants
EGFR Exon 19 Deletion Mutation · EGFR NP_005219.2:p.L858R · Lung Non-Squamous Non-Small Cell Carcinoma
Primary: Progression Free Survival (PFS) — 13.5; 17.9 months — p=0.39
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 2 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Non-Small Cell Lung Cancer
Primary: Progression Free-survival — 9.4; 5.2 months — p=0.0001
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-free Survival — 11.01; 5.59 months — p=<0.0001
Non Small Cell Lung Cancer · Lung Cancer
Primary: Number of Patients With Pathologic Complete Response Rate — 1; 1; 2; 2 participants
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
Primary: Progression-Free Survival (PFS) Rate at 12-months — 9; 11 Participants — p=0.367
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
Advanced Non-small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (Phase I Part) — 0; 0; 2; 0 Participants
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Lung Neoplasms
Primary: Progression-free Survival — 12.78; 11.17 Months — p=0.0891
Locally Advanced or Metastatic NSCLC
Primary: Objective Response Rate — 0 Participants
NSCLC Stage IIIB · NSCLC Stage IV · EGFR Gene Mutation
Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 39; 33 Participants
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
Carcinoma, Non-Small-Cell Lung · Adenocarcinoma
Primary: Progression-Free Survival (PFS) Time — 11.17; 6.90 Months. — p=0.0002
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Endpoint is the Occurrence of Dose Limiting Toxicity (DLT). — 0; 0 participants
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Duration of Progression-free Survival — 11.0; 5.5 Months
Lung Neoplasms · Squamous Cell Lung Cancer · Adenocarcinoma of the Lung
Primary: 3-year Disease-Free Survival — 96.1; 84.0 Percentage of patients at 3 years
Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants
Non-Small-Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR) — 5.59; 1.54; 5.45 Months — p=0.0528
Carcinoma, Non-Small-Cell Lung
Primary: Phase I Step: Safety of BIBW 2992 Assessed Based on Incidence of Dose Limiting Toxicity (DLT) and Incidence & Intensity of Adverse Events According to CTCAE — 3; 3; 6; 3…
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-free Survival (Tumour Assessments According to RECIST Criteria) — 223 Days
Lung Cancer
Primary: Progression Free Survival — 16; 10.5 months